Live Breaking News & Updates on Allogeneic Hematopoietic Stem Cell Transplantation Hsct

1. Median progression-free survival in the HSCT group was significantly longer than in the non-HSCT group. 2. HSCT was associated with a slightly increased risk of serious adverse events, including graft-versus-host disease (59% vs. 44%, respectively). Evidence Rating Level: 2 (Good) Study Rundown: Advanced cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of ....

Rating Level , Second Line Tisagenlecleucel , Standard Care , Aggressiveb Cell , Between Jun , Allogeneic Hematopoietic Stem Cell Transplantation , Allogeneic Hematopoietic Stem Cell Transplantation Hsct , Cutaneoust Cell Lymphoma , Stem Cell Transplant , T Cell Lymphoma , Chronic Disease ,